Twist Bioscience (TWST) CAO sells 1,051 shares in tax sale

Twist Bioscience Corp (TWST) reported insider share sales by its Chief Accounting Officer.

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported insider share sales by its Chief Accounting Officer. The reporting person sold 229 shares of common stock on 11/21/2025 at a price of $26.5035 per share and 822 shares on 11/24/2025 at a price of $28.7095 per share. After these transactions, the officer beneficially owned 66,143 shares of Twist Bioscience common stock in direct ownership.

According to the explanation, the 229 and 822 shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plans, and the sales did not represent discretionary trades by the officer.

Insider Trade Summary

Net Seller: 1,051 shares

Net Sell 2 txns

Insider WERNER ROBERT F.

Role Chief Accounting Officer

Sold 1,051 shs ($30K)

Type	Security	Shares	Price	Value
Sale	Common Stock	822	$28.7095	$24K
Sale	Common Stock	229	$26.5035	$6K

Holdings After Transaction: Common Stock — 66,143 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) disclose in this Form 4?

The filing discloses that Twist Bioscience's Chief Accounting Officer sold 229 shares of common stock on 11/21/2025 and 822 shares on 11/24/2025.

At what prices were the Twist Bioscience (TWST) shares sold in this Form 4?

The reported sales were executed at $26.5035 per share for the 229 shares and $28.7095 per share for the 822 shares of Twist Bioscience common stock.

How many Twist Bioscience (TWST) shares does the reporting person own after these transactions?

Following the reported transactions, the Chief Accounting Officer beneficially owned 66,143 shares of Twist Bioscience common stock in direct ownership.

Why were the Twist Bioscience (TWST) shares sold according to the Form 4 explanation?

The filing states that the 229 and 822 shares were sold to cover tax withholding obligations related to the vesting of restricted stock units under the company’s equity incentive plans.

Were the insider sales by the Twist Bioscience (TWST) officer discretionary trades?

No. The explanation notes that these sales were mandated by the issuer’s election to fund tax withholding via a "sell to cover" transaction and do not represent discretionary trades by the reporting person.

What is the role of the reporting person at Twist Bioscience (TWST)?

The reporting person is identified as an officer of Twist Bioscience Corp, serving in the role of Chief Accounting Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/25/2025 - 04:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WERNER ROBERT F.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		S		229(1)	D	$26.5035	66,965	D
Common Stock	11/24/2025		S		822(1)	D	$28.7095	66,143	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.